The current stock price of CBUS is 2.21 USD. In the past month the price decreased by -9.68%. In the past year, price decreased by -10.76%.
ChartMill assigns a technical rating of 7 / 10 to CBUS. When comparing the yearly performance of all stocks, CBUS is one of the better performing stocks in the market, outperforming 88.05% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to CBUS. CBUS may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months CBUS reported a non-GAAP Earnings per Share(EPS) of -2.66. The EPS increased by 82.01% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -36.01% | ||
| ROE | -235.91% | ||
| Debt/Equity | 0 |
10 analysts have analysed CBUS and the average price target is 14.69 USD. This implies a price increase of 564.62% is expected in the next year compared to the current price of 2.21.
For the next year, analysts expect an EPS growth of 18.82% and a revenue growth -2.44% for CBUS
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.5 | 387.092B | ||
| AMGN | AMGEN INC | 16.77 | 198.053B | ||
| GILD | GILEAD SCIENCES INC | 17.02 | 185.32B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.24 | 116.409B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.82 | 80.573B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.79 | 43.76B | ||
| INSM | INSMED INC | N/A | 32.21B | ||
| NTRA | NATERA INC | N/A | 27.199B | ||
| BIIB | BIOGEN INC | 12.62 | 27.192B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.53 | 20.623B |
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
Cibus, Inc. engages in the research and development of plant traits to seed companies for royalties. The company is headquartered in San Diego, California and currently employs 157 full-time employees. The company went IPO on 2017-07-20. Its business is the development of plant traits for some of the agricultural food crops that help address specific productivity, profitability, sustainability, or yield challenges in farming. Its core technology propriety gene editing platform is called the Rapid Trait Development System (RTDS). The company is the underlying technology in the Company's Trait Machine process, an end-to-end semi-automated high-throughput gene editing system that directly edits seed companies' elite germplasm. The company has a pipeline of five productivity traits. The company has developed the productivity trait Pod Shatter Reduction (PSR) in Canola and Winter Oilseed Rape (WOSR) strengthens the sheath around the canola seeds. Its advanced productivity traits, Sclerotinia resistance and HT2 in Canola and WOSR, continue to progress and offer white mold disease resistance and broadleaf weed herbicide tolerance.
CIBUS INC
6455 Nancy Ridge Drive
San Diego CALIFORNIA US
Employees: 157
Phone: 18584500008
Cibus, Inc. engages in the research and development of plant traits to seed companies for royalties. The company is headquartered in San Diego, California and currently employs 157 full-time employees. The company went IPO on 2017-07-20. Its business is the development of plant traits for some of the agricultural food crops that help address specific productivity, profitability, sustainability, or yield challenges in farming. Its core technology propriety gene editing platform is called the Rapid Trait Development System (RTDS). The company is the underlying technology in the Company's Trait Machine process, an end-to-end semi-automated high-throughput gene editing system that directly edits seed companies' elite germplasm. The company has a pipeline of five productivity traits. The company has developed the productivity trait Pod Shatter Reduction (PSR) in Canola and Winter Oilseed Rape (WOSR) strengthens the sheath around the canola seeds. Its advanced productivity traits, Sclerotinia resistance and HT2 in Canola and WOSR, continue to progress and offer white mold disease resistance and broadleaf weed herbicide tolerance.
The current stock price of CBUS is 2.21 USD. The price decreased by -1.34% in the last trading session.
CBUS does not pay a dividend.
CBUS has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
10 analysts have analysed CBUS and the average price target is 14.69 USD. This implies a price increase of 564.62% is expected in the next year compared to the current price of 2.21.
CIBUS INC (CBUS) currently has 157 employees.